Genomtec SA
F:4VI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Genomtec SA (4VI) under the Base Case is 0.078 EUR per share. Compared with the current market price of 0.494 EUR, the stock appears Overvalued by 84% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Genomtec Does
Genomtec is a Polish life-science company that develops molecular diagnostics tools for detecting genetic material from pathogens and other biological samples. Its core work centers on laboratory and point-of-care testing systems, including the test cartridges and instruments needed to run them. The company sells its technology into healthcare and diagnostics, where fast and accurate identification of infections matters.
- Headquarters
- Poland PL
- IPO date
- Mar 17, 2021
Balance Sheet
Continue 4VI Research
Decided on Genomtec? Get an email when 4VI reaches the price you’d buy at. Free with an account.
Other Genomtec listings
What is the Intrinsic Value of one 4VI stock?
The intrinsic value for Genomtec SA (4VI) under the Base Case is 0.078 EUR.
Is 4VI stock undervalued or overvalued?
Compared with the current market price of 0.494 EUR, the stock appears Overvalued by 84% .